Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

BACKGROUND: Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed and refractory (R/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further therapies will be. Moreover,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Carreau, Nicole A., Pail, Orrin, Armand, Philippe, Merryman, Reid, Advani, Ranjana H., Spinner, Michael A., Herrera, Alex, Chen, Robert, Tomassetti, Sarah, Ramchandren, Radhakrishnan, Hamid, Muhammad S., Assouline, Sarit, Santiago, Raoul, Wagner‐Johnston, Nina, Paul, Suman, Svoboda, Jakub, Bair, Steven, Barta, Stefan, Liu, Yang, Nathan, Sunita, Karmali, Reem, Burkart, Madelyn, Torka, Pallawi, David, Kevin, Wei, Catherine, Lansigan, Frederick, Emery, Lukas, Persky, Daniel, Smith, Sonali, Godfrey, James, Chavez, Julio, Xia, Yuhe, Troxel, Andrea B., Diefenbach, Catherine
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Hematologic Malignancies
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543382/
https://ncbi.nlm.nih.gov/pubmed/32720734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0167
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items